dc.contributor
Institut Català de la Salut
dc.contributor
[Altena R] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Breast cancer, Endocrine tumors and Sarcoma, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. [Bajalica-Lagercrantz S] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. [Papakonstantinou A] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Breast cancer, Endocrine tumors and Sarcoma, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Altena-Kornalijnslijper, Renske
dc.contributor.author
Bajalica Lagercrantz, Svetlana
dc.contributor.author
Papakonstantinou, Andri
dc.date.accessioned
2025-10-25T05:38:15Z
dc.date.available
2025-10-25T05:38:15Z
dc.date.issued
2022-10-26T12:20:00Z
dc.date.issued
2022-10-26T12:20:00Z
dc.date.issued
2022-09-25
dc.identifier
Altena R, Bajalica-Lagercrantz S, Papakonstantinou A. Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies. Cancers. 2022 Sep 25;14(19):4665.
dc.identifier
https://hdl.handle.net/11351/8351
dc.identifier
10.3390/cancers14194665
dc.identifier
000866781800001
dc.identifier.uri
http://hdl.handle.net/11351/8351
dc.description.abstract
Breast cancer; Cardiotoxicity; Pharmacogenomics
dc.description.abstract
Cáncer de mama; Cardiotoxicidad; Farmacogenómica
dc.description.abstract
Càncer de mama; Cardiotoxicitat; Farmacogenòmica
dc.description.abstract
Pharmacogenomics is an emerging field in oncology, one that could provide valuable input on identifying patients with inherent risk of toxicity, thus allowing for treatment tailoring and personalization on the basis of the clinical and genetic characteristics of a patient. Cardiotoxicity is a well-known side effect of anthracyclines and anti-HER2 agents, although at a much lower incidence for the latter. Data on single-nucleotide polymorphisms related to cardiotoxicity are emerging but are still scarce, mostly being of retrospective character and heterogeneous. A literature review was performed, aiming to describe current knowledge in pharmacogenomics and prediction of cardiotoxicity related to breast cancer systemic therapies and radiotherapies. Most available data regard genes encoding various enzymes related to anthracycline metabolism and HER2 polymorphisms. The available data are presented, together with the challenges and open questions in the field.
dc.description.abstract
This study was supported by a grant from Percy Falks Stiftelse to A.P.
dc.format
application/pdf
dc.relation
Cancers;14(19)
dc.relation
https://doi.org/10.3390/cancers14194665
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Tractament
dc.subject
Farmacogenòmica
dc.subject
Toxicologia cardiovascular
dc.subject
DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Biology::Genetics::Pharmacogenetics
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
DISEASES::Chemically-Induced Disorders::Drug-Related Side Effects and Adverse Reactions::Cardiotoxicity
dc.subject
DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::genética::farmacogenética
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ENFERMEDADES::trastornos inducidos químicamente::efectos colaterales y reacciones adversas relacionados con medicamentos::cardiotoxicidad
dc.title
Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
